ARQT vs. QCOM
ARQT (Arcutis Biotherapeutics, Inc.) and QCOM (QUALCOMM Incorporated) are both stocks. ARQT operates in Biotechnology (Healthcare), while QCOM operates in Semiconductors (Technology). Over the past 5 years, ARQT returned -4.14%/yr vs 15.61%/yr for QCOM. At a 0.23 correlation, their price movements are largely independent.
Performance
ARQT vs. QCOM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARQT achieves a -26.48% return, which is significantly lower than QCOM's 47.10% return.
ARQT
- 1D
- 2.69%
- 1M
- -9.11%
- YTD
- -26.48%
- 6M
- -28.74%
- 1Y
- 60.89%
- 3Y*
- 37.57%
- 5Y*
- -4.14%
- 10Y*
- —
QCOM
- 1D
- 3.81%
- 1M
- 48.48%
- YTD
- 47.10%
- 6M
- 44.46%
- 1Y
- 71.79%
- 3Y*
- 31.99%
- 5Y*
- 15.61%
- 10Y*
- 19.54%
ARQT vs. QCOM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | -26.48% | 108.47% | 331.27% | -78.18% | -28.64% | -26.27% | 29.04% |
QCOM QUALCOMM Incorporated | 47.10% | 13.84% | 8.31% | 35.07% | -38.58% | 22.25% | 83.14% |
Correlation
The correlation between ARQT and QCOM is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2020 | 0.23 |
Fundamentals
ARQT:
$2.76B
QCOM:
$268.01B
ARQT:
-$0.02
QCOM:
$9.11
ARQT:
6.74
QCOM:
6.12
ARQT:
14.56
QCOM:
9.83
ARQT:
$415.62M
QCOM:
$44.49B
ARQT:
$377.98M
QCOM:
$24.38B
ARQT:
$12.21M
QCOM:
$12.92B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARQT vs. QCOM — Risk / Return Rank
ARQT
QCOM
ARQT vs. QCOM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and QUALCOMM Incorporated (QCOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ARQT | QCOM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.51 | ||
| Sortino ratioReturn per unit of downside risk | -0.45 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.33 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 1.63 | 2.18 | -0.55 |
| Martin ratioReturn relative to average drawdown | 3.90 | 4.92 | -1.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ARQT | QCOM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.06 | 1.57 | -0.51 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.06 | 0.39 | -0.45 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.50 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.00 | 0.43 | -0.44 |
Drawdowns
ARQT vs. QCOM - Drawdown Comparison
The maximum ARQT drawdown since its inception was -95.02%, which is greater than QCOM's maximum drawdown of -86.75%. Use the drawdown chart below to compare losses from any high point for ARQT and QCOM.
Loading charts...
Drawdown Indicators
| ARQT | QCOM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.02% | -86.75% | -8.27% |
Max Drawdown (1Y)Largest decline over 1 year | -37.50% | -33.13% | -4.37% |
Max Drawdown (3Y)Largest decline over 3 years | -83.24% | -44.23% | -39.01% |
Max Drawdown (5Y)Largest decline over 5 years | -93.67% | -44.29% | -49.38% |
Max Drawdown (10Y)Largest decline over 10 years | — | -44.29% | — |
Current DrawdownCurrent decline from peak | -42.27% | -0.40% | -41.87% |
Average DrawdownAverage peak-to-trough decline | -50.15% | -32.89% | -17.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.65% | 14.65% | +1.00% |
Volatility
ARQT vs. QCOM - Volatility Comparison
The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 20.15%, while QUALCOMM Incorporated (QCOM) has a volatility of 28.47%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than QCOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARQT | QCOM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.15% | 28.47% | -8.32% |
Volatility (6M)Calculated over the trailing 6-month period | 36.79% | 38.80% | -2.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.58% | 45.89% | +11.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.79% | 40.55% | +31.24% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 76.98% | 38.95% | +38.03% |
Dividends
ARQT vs. QCOM - Dividend Comparison
ARQT has not paid dividends to shareholders, while QCOM's dividend yield for the trailing twelve months is around 1.42%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
QCOM QUALCOMM Incorporated | 1.42% | 2.06% | 2.18% | 2.18% | 2.67% | 1.47% | 1.69% | 2.81% | 4.27% | 3.50% | 3.17% | 3.72% |
Financials
ARQT vs. QCOM - Financials Comparison
This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and QUALCOMM Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARQT vs. QCOM - Profitability Comparison
ARQT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 95.61M and revenue of 105.40M. Therefore, the gross margin over that period was 90.7%.
QCOM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, QUALCOMM Incorporated reported a gross profit of 5.70B and revenue of 10.60B. Therefore, the gross margin over that period was 53.8%.
ARQT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported an operating income of -9.09M and revenue of 105.40M, resulting in an operating margin of -8.6%.
QCOM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, QUALCOMM Incorporated reported an operating income of 2.31B and revenue of 10.60B, resulting in an operating margin of 21.8%.
ARQT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported a net income of -11.30M and revenue of 105.40M, resulting in a net margin of -10.7%.
QCOM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, QUALCOMM Incorporated reported a net income of 7.37B and revenue of 10.60B, resulting in a net margin of 69.5%.
Frequently Asked Questions
ARQT and QCOM have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QCOM has higher volatility (28.47%) compared to ARQT (20.15%). In terms of maximum drawdown, ARQT dropped -95.02% vs QCOM's -86.75%.
QCOM currently has the higher Sharpe Ratio (1.57 vs 1.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARQT and QCOM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer